Amynas gets positive patent search report for NanoBiotics technology

By AI, Created 3:36 PM UTC, June 03, 2026, /AGP/ – Amynas said the European Patent Office issued a positive International Search Report for its PCT application covering NanoBiotics™, a step the company says strengthens its global IP position and supports future commercialization. The report also sets up a planned U.S. utility patent filing as Amynas advances toward market entry in implant infection prevention.

Why it matters: - A positive International Search Report from the European Patent Office can improve the odds of patent protection for Amynas’ core NanoBiotics™ platform. - Stronger intellectual property could support fundraising, commercialization and future licensing efforts for the implant infection-prevention technology. - The patent application covers a technology aimed at reducing rejection and infection in medical implants, including drug-resistant hospital strains.

What happened: - Amynas announced receipt of a positive International Search Report from the European Patent Office for its PCT patent application. - The application covers the company’s core NanoBiotics™ technology. - The company said the favorable assessment highlights the novelty and uniqueness of its nanofiber technology. - CEO Lode Debrabandere said the report is a strong validation of the originality of the technology. - Debrabandere said DLA Piper has helped articulate and protect the inventive aspects of the surgical implant infection-protection platform.

The details: - The technology is designed to solve two costly implant problems: device rejection or failure to integrate safely and infection. - The platform uses a device-agnostic nanofiber envelope that mimics the body’s native extracellular matrix. - The biomimetic structure is designed to promote healthy, vascularized tissue growth and reduce scar tissue and adhesion formation. - The nanofibers embed rifampin and minocycline for gradual, uniform antibiotic release. - Amynas said the release profile differs from coated antibiotics that can discharge too quickly. - The company said a defensible IP portfolio is central to its development and commercialization strategy. - Amynas said the positive search results increase confidence as it evaluates national phase entries and advances its product pipeline. - Based on the report, Amynas expects to apply for a U.S. utility patent for the same technology.

Between the lines: - A favorable search report does not equal a granted patent, but it can signal that examiners found the invention potentially novel and patentable. - The company is trying to lock in protection before broader commercialization, which is especially important in medtech categories with long regulatory and market timelines. - Shepherd Ventures III’s plan to lead a later scaling round suggests investor interest, but only after the technology is on the market and ready to expand.

What’s next: - Amynas plans to pursue national phase entries and seek a U.S. utility patent for the NanoBiotics technology. - Shepherd Ventures III said it expects to lead the first scaling round, likely a Series A, after the technology reaches market in its beachhead segments. - The company is also offering a seed round of up to $7.5 million on attractive terms before patent grant and FDA clearance. - Amynas is targeting cardiovascular implantable electronic devices, neurostimulator devices and orthopedic implant devices.

The bottom line: - Amynas has a meaningful patent milestone, but the bigger test is whether the company can turn that IP momentum into regulatory progress, market adoption and scalable financing.